COVID Cure: DCGI approves Itolizumab for restricted emergency use
It is for the treatment of ‘cytokine’ release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.
New Delhi: India's drug regulator has approved Itolizumab, a medicine used to cure psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, informed officials.Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon for several years, for restricted emergency use. It is for the treatment...
New Delhi: India's drug regulator has approved Itolizumab, a medicine used to cure psoriasis for "restricted emergency use" to treat COVID-19 patients with moderate to severe acute respiratory distress, informed officials.
Dr V G Somani, approved monoclonal antibody injection Itolizumab, an already approved drug of Biocon for several years, for restricted emergency use. It is for the treatment of 'cytokine' release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19, they said.
"The approval was given after its clinical trials on COVID-19 patients in India was found satisfactory by the expert committee comprising pulmonologists, pharmacologists and medical experts from AIIMS, among others, for treatment of cytokine release syndrome," an official told PTI.
Written informed consent of each patient is required before the use of this drug, he said.
Read also: Serum Institute of India COVID vaccine anticipates DCGI nod by 2020 end
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd